Sign in
Taking people in South KoreaNo phase

Testing Drug Responses Using Tumor Models Grown From Glioblastoma Patients

Studies whether lab-grown tumor models from patients predict how glioblastoma responds to treatment.

Key facts

Who runs it
Chungnam National University Hospital
Where
Daejeon, South KoreaSee the site
Trial code
Registry title
Drug Response Testing and Repurposing Using Glioblastoma Organoid
Status
Recruiting
People taking part
150 people, planned
Started
18 Aug 2021
Expected to end
Dec 2030
Type of study
Observational
Treatments tested
  • Organoid-based drug sensitivity test
Record updated
20 January 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people with primary or recurrent glioblastoma who had standard treatment and have enough tumor tissue to grow an organoid in the lab.

Sex
All sexes can join.
Disease stage
Primary or recurrent glioblastoma.
Earlier treatment
Standard treatment with surgery and chemoradiation therapy that includes temozolomide.

Main reasons for not taking part

  • Did not have concurrent chemoradiation therapy (CCRT) after surgery
  • No MRI scan could be obtained after CCRT
  • Refuses to take part

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • primary or recurrent glioblastoma
  • patients treated with standard treatment including surgery and temozolomide based chemoradiation therapy
  • sufficient tumor sample is available for organoid culture

Who cannot take part

  • patients who are not underwent concurrent chemoradiation therapy (CCRT) following surgery
  • failed to obtain MRI scan after CCRT
  • patients refusal

Where in South Korea

  • Chungnam National University HospitalDaejeon, South KoreaContact: Kyung Hwan Kim, MD, PhDTaking people

About the trial

What the trial wants to find out

The aim of this observational study, based on a prospectively collected cohort, is to evaluate the prognostic value of patient-derived organoids in predicting responses to conventional and repurposing drugs, including temozolomide, in patients with primary or recurrent glioblastoma. The primary question is whether the patient's response to temozolomide is recapitulated in their corresponding patient-derived glioblastoma organoid (GBO). Patient drug responses are evaluated using survival data, while GBO drug responses are assessed through a drug-response testing platform utilizing cell viability assays. Additionally, this platform is used to explore the potential application of various chemotherapeutic agents.

The group in the trial

  • glioblastoma

    prospectively enrolled

    Treatment: Organoid-based drug sensitivity test

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Patient-derived Organoids As Predictive Models for Drug Response Testing and Repurporsing in Glioblastoma Therapy
Plain-language title
Testing Drug Responses Using Tumor Models Grown From Glioblastoma PatientsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
20 January 2025